Trial Profile
Randomized, Double-blind, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Piromelatine (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Acronyms MAD
- 06 Apr 2011 Actual end date (1 Apr 2011) added as reported by ClinicalTrials.gov.
- 06 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2010 Planned end date changed from 1 Nov 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.